A recent meta-analysis of 11 RCTs that assessed the safety and efficacy endpoints of SGLT2 inhibitors in T1D demonstrated that the use of SGLT2 inhibitors resulted in a significant reduction in albuminuria (by 23.13%), and this effect was consistent across all of the SGLT2 inhibitors used [25]. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.